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Novel antifungals
Efforts to discover new antifungal agents continue due to the perceived threat of emerging
new pathogenic fungi as well as resistance to existing therapy. The triazole class of drugs
remains the mainstay of therapy for systemic life threatening fungal infections. These drugs,
known as azole antifungals, share a common mode of action in that they inhibit Cyt-P450
dependent sterol 14-α-demethylase. Inhibition of this enzyme results in depletion of
ergosterol, an essential sterol for fungal cell membrane synthesis. Nearly all azole antifungals
are N-substituted azoles and share the azolyl phenethyl amine pharmacophore (i). The
synthesis of focused libraries containing the 1H-imidazole-4-methylaminosulphonamide motif,
with the aim of discovering potent new antifungal lead compounds, is described (Novel
antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead
discovery and optimisation, A. K. Saha et. al., Bioorg. Med. Chem. Lett., 10, (2000), 2175-
2178).
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(i): X = Cl or F; Y,Z = O, O or O, C
A library of more than 1000 individual compounds was synthesised on a 1H-imidazole-4-
carboxaldehyde immobilised, 2-chlorotrityl chloride polystyrene solid phase resin. Screening of
these compounds against eight isolates of Candida spp., for their in vitro antifungal activity,
revealed a number of active compounds. One of the most potent compounds discovered was
(ii) which possessed an IC50 of 26 nM against ergosterol. This library has been successful in
providing a novel series of antifungal imidazoles, some of which possessed potent anti-
Candida activity. These active compounds inhibit the synthesis of fungal ergosterol synthesis.
Future work may be directed at further optimisation of this pharmacophore to deliver even
more potent anti-Candida compounds.
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DNA topoisomerase II inhibitors
The effective treatment regimens to decrease microfilaramia have been primarily responsible
for the recent designation by the World Health Assembly of lymphatic filariasis as a disease
that can be eliminated globally. Human lymphatic filariasis, which is caused by helminths
Wuchereria bancrofti (90% of cases) and Brugia malayi (10% of cases), affects
approximately 120 million people. The challenge of drug discovery lies in the identification of
novel therapeutic targets from the myriad of parasite enzymes, receptors, genome data and
metabolic pathways. The potential antifilarials known either act on the membrane receptors or
on metabolic enzymes. DNA topoisomerases are cellular enzymes that are intricately involved
in maintaining the topographic structure of DNA, transcription and mitosis. Topoisomerase
has been identified as an important biochemical target in cancer chemotherapy and microbial
infections. Intracellular bacteria have been detected in most filarial worms, and it is thought
that by eradicating the endobacteria, filarial parasites may also die due to disturbance in the
endosymbiosis. Recently, DNA topoisomerase II (topo II) of the filarial parasites has been
identified as a target for the development of antifilarial compounds, hence enabling study of
the effect of various inhibitors of topoisomerases and antifilarials (Identification of inhibitors of
DNA topoisomerase II from a synthetic library of glycoconjugates, R. P. Tripathi et. al.,
Combi. Chem. & High Throughput Screen., 4, (2001), 237-244). A small library of 24
compounds was synthesised on solid phase from Sieber amide resin. One of the most potent
compounds isolated was (iii) which gave 95% inhibition of DNA topoisomerase II of filarial
parasite Setaria cervi. This library has provided a novel low molecular weight pharmacophore
with potent DNA topo II inhibitory activity. Since no satisfactory inhibitor for topo II of S.
cervi is currently available, glycoconjugate (iii) lays the foundation for the design of more
potent inhibitors.
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